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ABSTRACT 
Studies were performed in the rabbit aortic rings, precontracted 
with norepinephrine, to determine the subtype(s) of muscarinic 
receptors involved in endothelium-dependent relaxation and con-
traction in the absence of endothelium elicited by cholinergic 
stimuli. Acetylcholine (ACh) and arecaidine propargyl ester (APE), 
a M2 and M3 agonist, produced a dose-dependent relaxation and 
contraction in endothelium-intact and endothelium-denuded 
rabbit aortic rings, respectively. 80th of these responses 
were blocked by the muscarinic receptor antagonist atropine. 
M, selective agonist McN-A-343 14-[N-(3-chlorophenyl)carba-
moyloxy]-2-butinyltrimethylammonium chloride 1 did not produce 
any effect on the tone of precontracted aortic rings. ACh- and 
APE-induced relaxation in aortic rings with intact endothelium 
was selectively blocked by M3 receptor antagonists hexahydro-
sila-difenidol and p-fluoro-hexahydro-sila-difenidol (pA2 of 7.84 
and 7.18) but not by M, antagonist pirenzepine or M2 receptor 
There is a large body of evidence indicating that the various 
biological responses produced by cholinergic agonists in differ-
ent tissues are mediated through activation of different sub-
types of muscarinic receptors. The concept of heterogeneity of 
muscarinic receptors was first proposed on the basis of binding 
studies with muscarinic receptor agonists (Birdsall et aL, 1978) 
and later with antagonist pirenzepine, which discriminates 
between MI and M2 subtypes (Birdsall et al., 1980; Hammer et 
al., 1980). Subsequent studies have shown a heterogeneity 
among M2 muscarinic receptors, and M2 receptors are subdi-
vided further into M2 (M2a) and M3 (M2ß ) (For review see 
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antagonists AF-DX 116 111-(2-[(diethylamino)methyl]-1-piperidi-
nyl]acetyl)-5, 11-dihydro-6H-pyrido-[2,3-b][1 ,4 ]-benzo-diazepin-
6-onel and methoctramine. ACh- and APE-induced contraction 
was inhibited by M2 receptor antagonists AF-DX 116 and meth-
octramine (pA2 of 7.11 and 6.71) but not by pirenzepine, hex-
ahydro-sila-difenidol or p-fluoro-hexahydro-sila-difenidol. ACh-
and APE-induced relaxation or contraction were not altered by 
nicotinic receptor antagonist hexamethonium or cyclooxygenase 
inhibitor indomethacin. These data suggest that relaxation elic-
ited by cholinergic stimuli in endothelium-intact aortic rings is 
mediated via release of endothelium-derived relaxing factor con-
sequent to activation of M3 receptors located on endothelial cells, 
whereas the contraction in aortic rings denuded of their endothe-
lium is mediated via stimulation of M2 receptors located on 
smooth muscle cells. 
Mutschier et al., 1987). This subclassification is based mainly 
on the affinities of different antagonists such as AF-DX 116 
111-(2-[( diethylamino )methyl] -1-piperidinyl]acetyl)-5,11-dihy-
dro-6H-pyrido-[2,3-b][1,4]-benzo-diazepin-6-onel (M2 > MI > 
M3), methoctramine (M2 > MI > M3), HHSiD (M3 2! MI > M2) 
and p-F-HHSiD (M3 > MI > M2) (Melchiorre et al., 1987; 
Mutschier et al., 1987; Eltze, 1988a,b; Lambrecht et aL, 1988; 
Hammer et al., 1986; Waelbroeck et al., 1989; Lambrecht et al_, 
1989). Recent molecular cloning studies have demonstrated the 
existence of a family of five muscarinic receptor (ml-m5), all of 
which share the same proposed overall structure and large 
degree of sequence identity (Bonner et aL, 1987; Kubo et al., 
1986; Braun et al., 1987; Fukuda et aL, 1987; Peralta et al., 
1987a,b; Bonner, 1989; Buckley et al., 1989). The antagonist 
binding properties and tissue distribution of the cloned ml to 
m3 receptor proteins correspond closely to that of the pharma-
cologically defined subtypes MI to M3 (Buckley et al., 1989; 
Wess et aL, 1990). An M4 receptor found in rat striatum 
(Waelbroeck et al_, 1990), NG 108-15 cells and rabbit lung 
ABBREVIATIONS: HHSid, hexahydro-sila-difenidol; p-F-HHSiD, p-fluoro-hexahydro-sila-difenidol; ACh, acetylcholine; KHB, Krebs-Henseleit butter; 
NE, norepinephrine; APE, arecaidine propargyl ester; EDRF, endothelium-derived factor; cGMP, cyclic GMP. 
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(Lazareno et al., 1990) is considered the pharmacological cor-
relate of the M4 gene product. 
It is weH established that ACh and other muscarinic agonists 
in various vascular preparations including rabbit aorta produce 
relaxation which is dependent on an intact endothelium 
(Furchgott and Zawadski, 1980; Angus et al., 1983). In endo-
thelium-denuded vascular preparations, cholinergic agonists 
not only fail to cause relaxation but produce contraction 
(Furchgott and Bhadrakom, 1953; Furchgott and Zawadski, 
1980; Angus et al. , 1983). Because both the relaxation and 
contraction produced by cholinergic agents are blocked by 
atropine, they appear to be mediated via activation of musca-
rinic receptors. Whether these opposite effects of muscarinic 
agonists in blood vessels, viz, relaxation with intact endothe-
lium and contraction without endothelium is due to activation 
of distinct subtypes of muscarinic receptors is not known. 
Therefore, the purpose of the present study was to characterize 
the subtype of muscarinic receptors involved in the action of 
cholinergic stimuli on relaxation and contraction of endothe-
lium-intact and endothelium-denuded rabbit aortic rings, re-
spectively. The effect of ACh, selective MI agonist McN-A-343 
14-[N-(3-chlorophenyl)carbamoyloxy]-2-butinyltrimethylam-
monium chloride} (Hammer and Giachetti, 1982; Eltze et al., 
1988) and M2 and Ma agonist APE (Mutschier and Lambrecht, 
1984; Moser et al., 1989, 1990) were investigated on relaxation 
and contraction of endothelium-intact and endothelium-de-
nuded aortic rings, respectively, superfused with KHB in the 
absence and presence of muscarinic receptor antagonist atro-
pine, MI selective antagonist pirenzepine, M2 antagonists AF-
DX 116 (Hammer et al., 1986; Giachetti et al., 1986; Duckies et 
al., 1987; Jaiswal and Malik, 1988; Jaiswal et al. , 1988) and 
methoctramine (Melchiorre et al., 1987), as weH as Ma selective 
antagonists HHSiD (Mutschier et al., 1987; Lambrecht et al., 
1988; Waelbroeck et al., 1989) and p-F-HHSiD (Lambrecht et 
al., 1988, 1989). 
Methods 
Male New Zealand White rabbits (1.0-2.0 kg) (Myrtle's Rabbitry, 
Thompson Station, TN) were anesthetized i.v. with sodium pentobar-
bital, 30 mg/kg (Abbott Laboratory, North Chicago, IL), the abdomen 
was opened and heparin (100 U/kg) was administered into the vena 
cava. The aorta was removed carefully, to protect the endotheliallining, 
and transferred to a beaker containing gassed (95% O2 and 5% CO2) 
KHB of following composition (in millimolar): NaCl, 114; KCl, 4.7; 
KH2P04, 1.2; NaHCOa, 25.0; CaCI2, 2.5; MgS04, 1.2; and glucose, 5.5. 
The aorta was cleaned free of adhering fat and connective tissues and 
then cut into 2.5-mm wide transverse rings using a razor blade. Each 
aortic ring was mounted by means of two triangle-shaped nichrome 
wire (0.2 mm diameter) in a temperature-controlled (37°C) chamber, 
superfused with warmed (3TC) KHB at a rate of 3 ml/min and gassed 
with 95% O2 and 5% CO2• The upper nichrome wire of each ring was 
attached with a thread to the force displacement transducer (Grass FT 
03C) and the lower nichrome wire was fixed to the bottom of the 
chamber with a thread for the adjustment of the resting tension. 
Changes in isometrie tension were recorded on a Grass polygraph. 
Before the start of any experimental intervention, all rings were allowed 
to equilibrate for 60 min while superfused continuously with KHB. 
Endothelium was removed from some aortic rings by gently rubbing 
the intima with a wooden stick for 45 to 60 sec. The removal of 
endothelial cells were verified histologically using a silver-staining 
method (Abrol et al., 1984). 
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Experimental Protocol 
After eqilibration for 60 min at 37°C, rings were stretched to the 
previously determined optimum resting tension of 1.5 g. For relaxation 
studies, submaximal increase in tone was achieved by superfusing the 
aortic rings continuously with 10-7 M of NE, whereas for contraction 
studies aortic rings were superfused with 10-8 M of NE so as to maintain 
similar experimental conditions as in aortic rings with intact endothe-
lium. The following experimental protocols were used for endothelium-
intact and endothelium-denuded aortic rings. 
Protocol 1. These series of experiments were conducted to inves-
tigate the effect of muscarinic agonists ACh (0.001-10 nmol), McN-A-
343 14-[N-(3-chlorophenyl)carbamoyloxy)-2-butinyltrimethylammon-
ium chloride} (0.001-1000 nmol) or APE (0.001-10 nmol) to decrease 
and increase isometrie tension in endothelium-intact and in endothe-
lium-denuded aortic rings, respectively. After an equilibration period 
of 30 min, muscarinic agonists were administered as a bolus into 
superfusing solution contained in a volume of 100 ~l and the responses 
were recorded on a physiograph. The vehicle of these agents was also 
administered in an additional series of aortic rings during the same 
time period as muscarinic agonists. 
Protocol 2. The second series of experiments were performed to 
investigate the effect of muscarinic receptor agonists ACh and APE in 
the absence and presence of selective Mh M2 and Ma muscarinic 
receptor antagonists on the isometrie tension of aortic rings precon-
stricted with NE. The experimental protocol consisted of two or more 
periods depending upon the antagonists used. The rings were equili-
brated with antagonists for 30 min. ACh, APE (1-100 nmol) or their 
vehicle were administered during all periods. After the responses of 
aortic rings to ACh or APE were recorded, the rings were superfused 
with muscarinic receptor antagonists atropine (10-7 to 10-6 M), MI 
receptor antagonist pirenzepine (10-7 to 10-4 M), M2 receptor antago-
nists AF-DX 116 111-(2-[(diethylamino)methyl)-I-piperidinyl)acetyl)-
5,11-dihydro-6H-pyrido-[2,3-b) [I,4)-benzo-diazepin-6-one} (10-7 to 
10-4 M) or methoctramine (10-7 to 10-4 M), Ma receptor antagonists 
HHSiD (10-8 to 10-4 M) or p-F-HHSiD (10-8 to 10-4 M), at a lower 
concentration in second period and at a higher concentration in third 
or subsequent periods and the responses of aortic rings to muscarinic 
agents were determined. The effect of muscarinic agonists in the 
presence of the vehicle of the above muscarinic receptor antagonists 
were also examined on aortic rings during these time periods. 
Protocol 3. The third series of experiments were performed to 
determine the effect of nicotinic receptor antagonist hexamethonium 
(10-6 M) and cyclooxygenase inhibitor indomethacin (5.0 x 10-6 M) on 
the responses elicited by bolus injections of muscarinic agonists of the 
endothelium-intact and endothelium-denuded aortic rings precon-
stricted with NE, as in the second series of experiments. The effects of 
muscarinic receptor antagonists used in this study were also investi-
gated on the vasodilator effect of noncholinergic agent calcium iono-
phore A23187 (10-7 M). 
Drugs. The following drugs used in this study were purchased: ACh 
chloride, NE bitartrate, atropine sulfate, hexamethonium bromide and 
indomethacin (Sigma Chemical Co., St. Loius, MO); and methoctra-
mine (Research Biochemieals, Inc., Natick, MA). The following drugs 
were synthesized: APE, HHSiD and p-F-HHSiD (Mutschier and 
Hultzsch, 1973; Tacke et al., 1985). The following drugs were gifts: 
McN-A-343 (Dr. Hammer, Instituto de Angeli, Milan, Italy); pirenze-
pine; and AF-DX 116 (Boehringer Ingelheim Pharmaceuticals, Ridge-
field, CT). 
Data analysis. Data were expressed as the mean ± S.E.M. and 
comparisons between means were made using Student's t test. Differ-
ences between means were considered significant at P < .05. The 
decrease (vasodilation) and increase (vasoconstriction) in tension pro-
duced by cholinergic agonists was presented as percentage of change 
from the tension raised by superfusing the aortic rings with NE 
solution. The affinity of muscarinic receptor antagonists was deter-
mined according to Arunlakshana and Schild (1959) and expressed in 
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terms of pA. values. pA2 values (-log I(antagonist)/(dose ratio - I)}) 
for antagonists were determined as described by MacKay (1978). 
Results 
Effeet of ACh, MeN-A-343 and APE on isometrie ten-
sion in aortie rings preeontraeted with NE (fig. 1). ACh 
produeed a dose-dependent deerease in tension in NE (10-7 
M)-preeontraeted endothelium-intaet aortie rings, produeing a 
maximal effeet at 10 nmol. MeN-A-343, a seleetive Ml agonist, 
did not alter the tone in NE-preeontracted aortie rings even up 
to a dose of 1000 nmol; whereas, APE, a M2 and M3 reeeptor 
agonist, relaxed the NE-preeontraeted rings in a dose-depend-
ent fashion (fig. 1A). 
In isolated aortie rings denuded of their endothelium and 
submaximally preeontraeted with 10-8 M of NE, ACh at 0.1 to 
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Fig. 1. Dose-response eurves to ACh, APE or McN-A-343 in rings of 
rabbit aorta with intact endothelium (A) and in aortic rings denuded of 
their endothelium (B). Aortie rings were prepared with an intact endothe-
lium or endothelium was removed from the aortic rings by gently rubbing 
the intimal surface with a wooden stick for 30 to 60 sec and allowed to 
equilibrate for at least 60 min before applying any drug. After the induction 
of submaximal contraction with 10-7 M (endothelium-intact) or 10-8 M 
(endothelium-denuded) of NE, ACh, McN-A-343 and APE were adminis-
tered as a bolus in a volume of 100 !LI. 
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100 nmol inereased the tone in a dose-dependent manner, 
produeing a maximal effeet at 100 nmol. Further inerease in 
the dose of ACh did not produee an additional enhaneement of 
the eontraetile response (fig. 1B). MeN-A-343, a Mrreeeptor 
agonist, did not alter the eontraetile responses of aortie rings 
up to 1000 nmol (fig. 1B). Administration of APE at a dose of 
0.1 nmol did not have any effeet, but APE produeed a signifi-
cant inerease in the eontraetile responses of aortie rings at 1 to 
100 nmol in a dose-dependent manner. APE produeed a maxi-
mal response at 100 nmol. A further inerease in the dose of 
APE did not have any additive effeet on eontraetile responses 
(fig. 1B). Administration ofvehicle did not produee any ehanges 
in the tone of the aortie rings. 
Comparisons were made of the relative poteneies of ACh and 
APE to produee relaxation and eontraction in the endothelium-
intaet and endothelium-denuded aortie rings, respeetively 
(table 1). ACh and APE were nearly equipotent in produeing 
eontraetion in endothelium-denuded aortie rings and relaxation 
in endothelium-intaet aortie rings, but about 10- to 40-fold 
higher concentrations of these two agonists were necessary in 
denuded aortie rings to get an effect. 
Effeet of musearinie reeeptor antagonists on relaxa-
tion produeed by ACh and APE in endothelium-intaet 
aortie rings preeontraeted with NE. Effeet of ACh (fig. 
2-4). The effect of ACh (1 and 10 nmol) to produce relaxation 
of aortic rings with intact endothelium was reduced signifi-
cantly by the infusion of nonselective musearinic receptor 
antagonist atropine at 10-7 and 10-6 M (fig. 2A). Infusion of 
Ml-receptor antagonist pirenzepine at 10-7 M did not have any 
effect but at 10-6 M redueed the ACh (10 nmol)-induced relax-
ation from 26 ± 5 to 11 ± 2% (fig. 2B); a lO-fold inerease in 
the concentration of pirenzepine did not produce any further 
change. In the presence of M2 receptor antagonist AF-DX 116 
(10-7 and 10-6 M), the relaxation elicited by ACh was not 
altered (fig. 2C). A further increase in the concentration of AF-
DX 116 did not produce any change. Methoctramine (10-7 to 
10-6 M) also did not alter ACh-induced relaxation (data not 
shown). 
Figure 3 illustrates the effects of M3-receptor antagonists 
HHSiD and p-F-HHSiD on relaxation response produced by 
10 nmol of ACh. Lower concentration of HHSiD (10-8 M) did 
not alter the relaxing effect of ACh but at 10-7 M, HHSiD 
inhibited the relaxation produced by ACh from 44 ± 7 to 19 ± 
4% (n = 6; P< .05). Further inerease in the concentration of 
HHSiD to 10-6 M abolished the relaxation response to ACh 
(fig. 3A). p-F-HHSiD, another M3-reeeptor antagonist, at 10-8 
M, did not alter the relaxation response to ACh but reduced it 
at 10-7 and 10-6 M; increasing the p-F-HHSiD concentration 
to 10-5 M completely abolished the relaxation produced by ACh 
(fig. 3B). 
Analysis of the data according to Arunlakshana and Schild 
(1959) gave a straight line for both HHSiD and p-F-HHSiD 
TABlE 1 
Comparison of agonists EDso values on relaxation and contraction 
in endothelium-intact and endothelium-denuded rabbit aortic rings, 
respectively 
Agonist Endothelium-Intact Endothelium·Denuded ED,o ED50 
nmol nmol 
ACh 0.25 ± 0.08 10 ± 2.48 
APE 0.5 ± 0.099 5.0 ± 1.32 
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Fig. 2. Effects of muscarinic receptor antagonists atropine (AT) (A), 
pirenzepine (PZ) (8) and AF-DX 116 (C) on the decrease in tone elicited 
by ACh in endothelium-intact aortic rings precontracted with NE (10-7 
M). After measuring the relaxation in the presence of ACh in the first 
period, the rings were superfused with muscarinic receptor antagonists 
at a lower concentration in the second period and then with higher 
concentration in consecutive periods. ACh or its vehicle (VEH) was 
administered as a bolus in all periods. Data are expressed as means ± 
S.E.M .. 'Significant difference between values in the presence of an 
antagonist and its VEH (P < .05). 
against ACh-induced relaxation in the endotheliurn-intact aor-
tie rings (fig. 4). The pA2 values for atropine, HHSiD, p-F-
HHSiD and pirenzepine are given in table 2. Slopes of Schild-
plots were not signifieantly different frorn unity (P < .05). 
Effect of APE (fig. 5). The deerease in tension produeed 
by 10 nrnol of APE was inhibited by atropine (10-7 M) (fig. 
5A), whereas infusion of the MI-receptor antagonist pirenze-
pine at 10-6 but not at 10-7 M redueed the relaxation produced 
by APE (fig. 5B). The M2-reeeptor antagonist AF-DX 116 at 
10-6 or 10-5 M did not significantly alter the relaxation pro-
dueed by APE (fig. 5C). HHSiD at 10-8 M did not alter the 
relaxing action of APE. A 10-fold inerease in the HHSiD 
coneentration (10-7 M) produeed a signifieant deerease in re-
laxation caused by APE (frorn 33 ± 7 to 16 ± 2%, n = 4; P< 
. 05); a 5-fold inerease in the coneentration of HHSiD abolished 
the relaxation response to APE (fig. 5D). p-F-HHSiD also 
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Fig. 3. Effects of muscarinic receptor antagonists HHSiD (A) and p-F-
HHSiD (8) on relaxation elicited by ACh in endothelium-intact NE-precon-
tracted (10-7 M) aortic rings elicited by 10 nmol of ACh. After measuring 
the relaxation in the presence of ACh in the first period, the rings were 
superfused with HHSiD or p-F-HHSiD at a lower concentration in the 
second period and then with higher concentration in consecutive periods. 
ACh was administered as a bolus in all periods. Data are expressed as 
means ± S.E.M. 'Significant difference between values in the presence 
of an antagonist and its vehicle (VEH) (P < .05). 
3.---------------07----, 
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Fig. 4. Schild plot of the values obtained in the presence of HHSiD and 
p-F-HHSiD on ACh-induced relaxation in the endothelium-intact aortic 
rings precontracted with NE (10-7 M). The log of the dose ratio -1 is 
plotted as a function of the log of antagonist concentration. Each point 
is the mean (±S.E.M.) of three to five experiments. 
inhibited the relaxation produeed by APE in a eoneentration-
dependent pattern (data not shown). 
Effect of muscarinic receptor antagonists on the con-
tractile response produced by ACh and APE in endothe-
lium-denuded aortic rings precontracted with NE (figs. 
6-8). An inerease in contractile response to NE-preeontraeted 
endotheliurn-denuded aortie rings elicited by ACh (10 and 100 
nrnol) was abolished by 10-7 (fig. 6A) and 10-6 M of atropine 
(data not shown). Pirenzepine (MI reeeptor antagonist) at 10-6 
and 10-5 M did not alter it but reduced it at 10-4 M (fig. 6B) . 
A 10-fold inerease in the eoneentration of pirenzepine did not 
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TABLE 2 
PA2 va lues of muscarinic receptor antagonists on relaxation 
response induced by ACh in endothelium-intact rabbit aortic rings, 
calculated as described under "Methods" (data analysis) 
Values are means ± S.E.M. 
Antagonist 
Atropine 
HHSiD 
p-F-HHSiD 
Pirenze-
pi ne 
pA2 ± S.E.M. 
8.82 ± 0.24 
7.84 ± 0.13 
7.18 ± 0.13 
6.48 ± 0.58 
reduce further the response (data not shown). M2 receptor 
antagonist AF-DX 116 at 10-7 M did not alter the effect of 
ACh; an increase in the concentration of AF-DX 116 from 10-6 
to 5 X 10-5 M reduced the contractile response elicited by ACh 
in a concentration-dependent manner (fig. 7A). Methoctra-
mine, another M2 receptor antagonist, significantly reduced 
ACh-induced contractile response at a concentration of 10-6 to 
10-5 M (fig. 7B). 
HHSiD at 10-7 to 10-4 M did not alter the contractile 
response produced by ACh (fig. 7C). p-F-HHSiD (10-4 M), 
another M3 receptor antagonist used in this study, was also 
ineffective in inhibiting the contractile response of ACh or 
APE (data not shown). Figure 8 illustrates the Schild's plots of 
the antagonistic action of AF-DX 116 and methoctramine on 
the contractile response to ACh produced in endothelium-
denuded aortic rings. Table 3 shows the comparison of the pA2 
values of these antagonists for the endothelium -denuded aortic 
rings from Schild's plot regression analysis. Slopes of Schild-
plots were not significantly different from unity (P < .05). 
The APE-induced contractile response of endothelium-de-
nuded aortic ring was also significantly reduced by atropine 
(10-8 M), AF-DX 116 (10-5 M) and methoctramine (10-5 M) 
but not by pirenzepine (10-4 M), HHSiD (10-4 M) or p-F-
HHSiD (10-4 M) (data not shown). 
Effect of hexamethonium and indomethacin on the 
actions of ACh and APE on relaxation and contraction 
of endothelium-intact and endothelium-denuded aortic 
rings. Hexamethonium (10-6 M), a nicotinic receptor blocker, 
and indomethacin (5 X 10-6 M), a cyclooxygenase inhibitor, 
did not alter the relaxation or contraction produced by ACh or 
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APE (10 nmol) in endothelium-intact or endothelium-denuded 
aortic rings, respectively (data not shown). The relaxation 
elicited by 10-7 M of A 23187 (53 ± 9% of NE-induced tone) 
was not altered by any of the muscarinic receptor antagonist 
used in this study. 
Discussion 
Our recent studies in the isolated rabbit heart indicate that 
muscarinic receptor agonists ACh and APE produce coronary 
vasodilation followed by vasoconstriction and that the vasodi-
lator component of the coronary response is mediated through 
activation of the M3 (M2ß ) subtype of muscarinic receptors, 
whereas coronary vasoconstriction is mediated through acti-
vation ofthe M2 (M2a ) subtype of muscarinic receptors (Jaiswal 
et al., 1988). The present study, which was undertaken to 
determine the subtype of muscarinic receptors involved in the 
action of cholinergic agonists to produce relaxation and con-
traction in endothelium-intact and endothelium-denuded rab-
bit aortic rings, respectively, suggests that: 1) both relaxation 
and contraction produced by cholinergic stimuli in NE-precon-
tracted rabbit aortic rings is not due to activation of MI 
muscarinic receptor subtype; 2) relaxation produced by cholin-
ergic agents is due to release ofEDRF, consequent to activation 
of M3 muscarinic receptors located on endothelium; and 3) 
contractile response produced by cholinergic agents in rabbit 
aortic endothelium-denuded rings is due to activation of M2 
receptors located in smooth muscle. The conclusion that relax-
ation as weIl as contraction produced by cholinergic stimuli in 
the NE-precontracted rabbit aortic ring is not due to activation 
of MI subtypes of muscarinic receptors is based on our dem-
onstration that ACh and APE, a selective M2 muscarinic recep-
tor agonist, produced a concentration-dependent relaxation in 
endothelium-intact and contraction in endothelium-denuded 
aortic rings, whereas McN-A-343, a selective MI agonist, did 
not alter the tone of aortic rings with and without endothelium 
even up to 1000-nmol concentration. McN-A-343 also failed to 
influence vascular tone in the rabbit ear artery (DuckIes, 1988). 
That muscarinic receptors involved in the action of ACh or 
APE to produce relaxation and contraction in aortic rings with 
intact and denuded endothelium, respectively, are not of MI 
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Fig. 5. Effects of muscarinic receptor antagonists atropine 
(AT) (A), pirenzepine (PZ) (B), AF-DX 116 (C) and HHSiD 
(D) on APE-induced relaxation of endothelium-intact aortic 
rings precontracted with NE (10-7 M). After measuring the 
relaxation in the presence of APE in the first period, the 
rings were superfused with muscarinic receptor antago-
nists at a lower concentration in the second period and 
then with higher concentration in consecutive periods. APE 
was administered as a bolus in all periods. Data are 
expressed as means ± S.E.M. 'Significant difference be-
tween values in the presence of an antagonist and its 
vehicle (VEH) (P < .05) . 
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Fig. 6. Effects of muscarinic receptor antagonists atropine (AT) (A) and 
pirenzepine (PZ) (8) on contraction elicited by ACh (10 nmol) in endothe-
lium-denuded aortic rings partially precontracted with NE (10-8 M). After 
measuring the contraction in the presence of ACh in the first period, the 
rings were infused with muscarinic receptor antagonists at a lower 
concentration in the second period, and then with higher concentration 
in consecutive periods. ACh was administered as a bolus in all periods. 
Data are expressed as means ± S.E.M. 'Significant difference between 
values in the presence of an antagonist and its vehicle (VEH) (P < .05). 
subtype of receptors, was also suggested by our finding that 
atropine abolished the relaxation with a pA2 value of 8.82 ± 
0.24 and contraction with a pA2 value of 8.14 ± 0.02; whereas 
pirenzepine failed to alter the relaxation up to 10-7 M and 
reduced at 10-6 M. Hynes et al. (1986) have reported that 
muscarinic receptors involved in methacholine-induced relax-
ation in rabbit ear artery are not of the MI subtype of receptors 
because of their low affinity toward pirenzepine (pA2 = 6.5 ± 
0.1). In the rabbit and dog aorta (Yamanaka et al., 1986) and 
bovine basilar artery (Vanderheyden et al., 1986), pKi values 
of pirenzepine for muscarinic receptors were 6.8, 6.97 and 6.4, 
respectively. However, Eglen and Whiting (1985) found some-
what higher pA2 values for pirenzepine in the endothelium of 
rabbit aorta (7.6-7.9) and dog femoral artery (7.6), which are 
elose to that reported for MI receptors in the cervical ganglia 
(8.36) (Brown et al. , 1980; Eltze et al., 1988). Because these 
affinities of pirenzepine are not consistent with either MI or 
M2 subtypes of muscarinic receptors, Eglen and Whiting (1985) 
have suggested that the muscarinic receptors that mediate 
vascular smooth musele relaxation differs from all previously 
identified subtypes of muscarinic receptors. 
Our demonstration that HHSiD andp-F-HHSiD, which have 
high affinity for M3 receptors but not AF-DX116 and methoc-
tramine (10-4 M), M2 receptor antagonists, inhibited ACh- or 
APE-induced relaxation in aortic rings with intact endothe-
lium, suggests that vascular smooth musele relaxation caused 
by muscarinic receptor agonists is due to activation of M3 
receptors. The affinity of HHSiD for muscarinic receptors 
mediating relaxation in rabbit aorta (this study; pA2 = 7.84, 
table 2) was very similar to that obtained in other vascular 
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Fig. 7. Effects of muscarinic receptor antagonist AF-DX 116 (A), meth-
octramine (8) and HHSiD (C) on contraction elicited by ACh (10 nmol) in 
endothelium-denuded aortic rings partially precontracted with NE (10-8 
M). After measuring the contraction in the presence of ACh in the first 
period, the rings were infused with AF-DX 116, methoctramine or HHSiD 
at a lower concentration in the second period and then with higher 
concentration in consecutive periods. ACh was administered as a bolus 
in all periods. Data are expressed as means ± S.E.M. 'Significant 
difference between values in the presence of an antagonist and their 
respective vehicle (VEH) (P < .05). 
preparations (Duckles and Garcia-Villalon, 1990; Duckles et 
al., 1990). However, the pA2 (7.18; table 2) found for p-F-
HHSiD was at the lower end of the range reported for its 
affinity to its M3 receptors in smooth museles (Lambrecht et 
al., 1989; Eglen et al., 1990; Duckles, 1990). HHSiD and p-F-
HHSiD have also been reported to have greater affinity for 
muscarinic receptors in the ileum (M3) than the atrium (M2) 
(Lambrecht et al., 1988, 1989). Muscarinic receptors mediating 
relaxation of rat and rabbit aorta to ACh exhibited lower 
affinity for methoctramine and pirenzepine, respectively, sug-
gesting further that muscarinic receptors mediating relaxation 
in aorta are not of MI or M2 subtypes (Eglen et al., 1988; Choo 
et al. , 1986). Although pirenzepine reduced the ACh-induced 
Log M Concentration 
Fig. 8. Schild-plot of the values obtained in the presence of AF-OX 116 
and methoctramine on the contraction elicited by ACh in endothelium-
denuded aortic rings partially precontracted with NE (10-8 M). The log of 
the dose ratio -1 is plotted as a function of the log of antagonist 
concentration. Each point is the mean (±S.E.M.) of three to five experi-
ments. 
TABLE 3 
PA2 values of muscarinic receptor antagonists (pA2) on contraction 
response induced by ACh in endothelium-denuded rabbit aorlic 
rings, calculated as described under "Methods" (data analysis) 
Values are means ± S.E.M. 
Antagonist 
Atropine 
AF-OX 116 
Methoctramine 
pA2±S.E.M. 
8.14 ± 0.02 
7.11 ± 0.19 
6.67 ± 0.27 
relaxation in endothelium-intact tissue, the pA2 value (6.75 ± 
0.56) was comparable to that found by several investigators 
(ranged from 6.5-6.8) in other tissues (Choo et al., 1986; DuckIes 
and Garcia-VillaIon, 1990; Hynes et al., 1986) demonstrating 
the low affinity of pirenzepine for muscarinic receptor-media-
ting relaxation. Recently, it was demonstrated that, in rat 
pulmonaryartery muscarinic receptor,which mediates relaxa-
tion, it is also of M3 subtype (McCormack et al., 1988). 
In contrast to ACh- or APE-induced relaxation in aortic 
rings with intact-endothelium, the contraction produced by 
these agents in aortic rings denuded of their endothelia was 
inhibited by AF -DX 116 and methoctramine but not by HHSiD 
andp-F-HHSiD. These observations suggest that the contrac-
tion of vascular smooth muscle produced by ACh or APE in 
aortic rings denuded of their endothelium is mediated primarily 
via activation of M2 receptors. Muscarinic receptor-stimulated 
contractile response to cholinergic agonists, which is independ-
ent of endothelium, has also been observed in some other blood 
vessels, such as the bovine coronary artery (DuckIes, 1988), 
canine saphenous vein (O'Rourke and Vanhoutte, 1987) and 
pig coronary actery (Beny et al., 1986; Graser et al., 1986, 1987). 
In these blood vessels, calcium ionophore A23187 but not 
cholinergic agonists produced endothelium-dependent relaxa-
tion. Whether this is due to lack of muscarinic receptors on the 
endothelial cells, no release of ED RF (Furchgott and Zawadsky, 
1980) by muscarinic receptor activation or the predominance 
of M2 receptors on smooth muscle cells, which upon activation 
causes contraction, that masks relaxation mediated by the 
activation of M3 (M3) receptors on endothelium is not known. 
Our finding that ACh and APE produced relaxation of aortic 
rings with intact-endothelium and contraction after removal of 
endothelium suggest that relaxation caused by activation of M3 
receptors masks the contractile effect of these agents mediated 
via stimulation of M2 receptors in the smooth muscle cells. 
Whether the mechanism by which M3 receptor-mediated relax-
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ation masks contraction caused via M2 receptors could involve 
release ofEDRF from endothelial cells which in turn suppresses 
M2 receptor-mediated contraction by a physiological antago-
nism or by interfering with postreceptor events involved in 
vascular smooth muscle contraction remains to be determined. 
Inasmuch as vascular smooth muscle relaxation produced by 
cholinergic agonists has been shown to be due to release of an 
EDRF (Furchgott, 1983), most likely nitric oxide (Palmer et 
al., 1987; Ignarro et al., 1988), which stimulates soluble guanyl-
ate cyclase and increases production of cG MP in vascular 
smooth muscle (Katsuki et al., 1977), it is possible that cGMP 
by decreasing cellular levels of calcium (Collins et al. , 1986; 
Cornwell and Lincoln, 1989) attenuates M2 receptor-stimulated 
contraction of vascular smooth muscle by cholinergic agonists. 
Removal of endothelium causes loss of M3 receptors and asso-
ciated generation of EDRF and thereby allow expression of M2 
receptor-mediated contraction in response to cholinergic ago-
nists. Although there is overwhelming evidence of the release 
of EDRF from several blood vessels with intact-endothelium 
(Furchgott, 1983), studies using 3H or 1251 quinuclidinyl benzi-
late as a selective probe for muscarinic receptors have failed to 
provide evidence for the presence of these receptors on endo-
thelial cells in a variety of blood vessels from several different 
species (Summers et al., 1987; Stephenson and Summer, 1987s; 
Stephenson et al., 1988); muscarinic receptor ligand binding 
was observed in smooth muscle cells (Stephenson et al., 1988). 
However, arecent study by Sim and Manjeet (1989) has dem-
onstrated with [3H]ACh binding the existence of muscarinic 
receptors on endothelium as weIl as on smooth muscle in rabbit 
aorta. These observations suggest that endothelium-dependent 
relaxation caused by cholinergic agonists results from an indi-
rect mechanism involving smooth muscle muscarinic receptors, 
with the endothelium playing a permissive role, possibly in-
volving a mediator communicating from the smooth muscle to 
the endothelial cells to initiate the release of EDRF which, in 
turn, initiates smooth muscle relaxation. The possibility that 
the Ma receptors in the endotheIium have low affinity for 
quinuclidinyl benzilate cannot be excluded. Our finding that 
the relaxation of aortic rings elicited by ACh or APE was 
selectively blocked by M3 but not by M2 receptor antagonists 
and by the removal of endothelium strongly suggests that 
muscarinic receptors involved in ACh- or APE-induced relax-
ation are localized on the endothelium. Supporting this view 
are our recent observations that ACh enhanced prostagIandin 
synthesis via activation of M2 and M3 muscarinic receptors in 
the rabbit aortic rings with intact endothelia or in endothelial 
cells but not in endothelium-denuded aortic rings or aortic 
smooth muscle cells (Jaiswal and Malik, 1990; Jaiswal et al., 
1991). 
It should be noted that the pharmacology of the muscarinic 
receptors mediating relaxation and contraction, respectively, 
in rabbit aorta identified in the present study differs substan-
tially from that of the M4 receptors in the rat striatum (Wael-
broeck et al., 1990), rabbit lung and NG 108-15 cells (Lazareno 
et al., 1990), as weIl as from that of cloned m4 and ms receptors 
(Buckley et al. , 1989; Dorje et al., 1991). The rabbit aorta 
muscarinic receptors did not appear to correspond to the m4 
(M4) and ms receptor gene products because pirenzepine is able 
to recognize m4 (M4) and ms receptors with relatively high 
affinity (pKi = 7.1-7.5) (Buckley et al., 1989; Lazareno et al., 
1990; Waelbroeck et al., 1990; Wess et al., 1990), but reduced 
ACh- and APE-induced effects only at high concentration in 
1991 
our study in rabbit aorta. The affinities of AF-DX 116 (pKi = 
6.5-6.8; Dorje et al., 1990; Waelbroeek et al., 1990) and meth-
octramine (7.5-8.1; Dorje et al. , 1990; Lazareno et al. , 1990; 
Waelbroeek et al., 1990) for m4 (M4) reeeptors were found to be 
high, but these antagonists did not inhibit musearinie reeeptor-
mediated relaxation in rabbit aorta, excluding again the eon-
tribution of M4 reeeptors in this effeet. The bin ding affinities 
for m4 (M4) and ms reeeptors of HHSiD [m4 (M4): pKi = 7.4-
8.0; Buekley et al., 1989; Lazareno et al., 1990; Waelbroeek et 
al., 1990; m5: pKi = 7.2; Buekley et al., 1989] and p-F-HHSiD 
(m4: pKi = 7.5; m5 pKi = 7.0; Dorje et al., 1990) were found to 
be high but, in the present study, these antagonists did not 
inhibit ACh- and APE-indueed eontraetion in rabbit aorta. 
Thus, the musearinie reeeptor mediating eontraetion in rabbit 
aorta probably does not eorrespond to the m5 gene produet. In 
addition, AF-DX 116 (pKi = 5.5; Dorje et al., 1990) displayed 
low affinity for cloned m5 reeeptors, but potently inhibited 
ACh- and APE-indueed eontraction of rabbit aorta. In light of 
the above, it is highly improbable that musearinie m4 (M4) or 
ms reeeptors are involved in musearinie relaxation and eon-
traetion, respeetively, of rabbit aorta. 
In eonclusion, the present study demonstrates that ACh- and 
APE-indueed relaxation in rabbit aortie rings with intaet en-
dothelia is due to aetivation of Ma (M2ß ) reeeptors loeated on 
the endothelium, whereas the eontraetile response elieited by 
cholinergie agonists in aortie rings denuded of their endothelia 
appears to be due to aetivation of the M2 (M2,,) subtype of 
musearinie reeeptors loeated in the smooth muscle. The M2 
reeeptor-mediatedeontraction is probably masked by Ma reeep-
tor-mediated relaxation eaused by the release of EDRF. It is 
clear now that not all vaseular musearinie reeeptors belong to 
the same subelass, as also demonstrated for the musearinie 
reeeptors on smooth muscle of the eoronary (Ma) and basilar 
artery (M2) of the pig (V an Charldorop and Van Zwieten, 1989; 
Entzeroth et al., 1990). 
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